Home / Resource Library / Final phase 2 study results of acalabrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemiaFinal phase 2 study results of acalabrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia